Serum Versus Urinary Trace Elements (Copper, Zinc, Manganese, Cobalt, Aluminium) In Epileptic Children

Thesis
Submitted for Ph. D. Degree In
Medical Childhood Studies

618.32

By
Mohamed Taha Mohamed

M. Sc. Ped., Ain Shams University

Supervised By

Prof. Dr. Hamed Ahmed El-Khayat

Professor of Pediatrics Ain Shams University

Prof. Dr. Olweya Mohamed Abd El-Bakey

Assistant Professor of Medical Childhood studies (Child Psychiatry) Postgraduate institute of Childhood studies Ain Shams University


Dr. Moustafa Abd El-Aziz El-Hodhod

Lecturer of Pediatrics Ain Shams University

Ain Shams University 1997







Acknowledgment

First and foremost, Thanks to ALLAH. to whom I relate any success in achieving any work in my life.

Then, I would like to express my utmost gratitude, thankfullness and appreciation to Professor Dr. Hamed Ahmed El-Khayat, Professor of Pediatrics, Faculty of Medicine, Ain Shams Univeresity. It is a real pleasure to acknowledge his sincere encouragement and valuable guidance, I would also thank him for his honest help, constant advice, keen interest and guidance throughout the performance of this work.

I would like to extend my sincere gratitude and appreciation to Prof. Dr. Olweya Mohamed Abd El-Bakey, Assistant Professor of Medical Childhood Studies (Child Psychiatry), Post graduate Institute of Childhood Studies, Ain Shams University, I feel thankful to her unlimited help, patience, valuable advice and kind guidance.

I am faithfully grateful to Dr. Moustafa Abd El-Aziz El-Hodhod, Lecturer of Pediatrics, Faculty of Medicine, Ain shams University for his valuable assistance, instructive guidance, effective scientific supervision, cooperation which were essential for this work to be achieved.

ABSTRACT

Name of the student: Mohamed Taha Mohamed.

"SERUM VERSES URINARY TRACE ELEMENTS (COPPER, ZINC, MANGANESE, COBALT, ALUMINIUM) IN EPILEPTIC CHILDREN"

MEDICAL CHILDHOOD STUDIES. POSTGRADUATE INSTITUTE OF CHILDHOOD STUDIES. AIN SHAMS UNIVERSITY.

Convulsion are among the most common and potentially life-threatening events in infants and children. The possible involvement of trace elements in convulsive disorders has been given more attention in recent years. Therefore , this study aimed at evaluation of the state of aluminium , cobalt , copper , manganese and zinc in convulsive disorders affecting children and evaluation of the effect of antiepileptic therapy on these elements.

Regarding serum copper level, it was significantly lower among all primary epileptics compared to controls, however, significant increase was noticed after AED.

Urinary copper level was significantly higher among all primary epileptics than controls when each AED was studied separately. There was no significant difference among epileptics before and after therapy.

As regards serum manganese, epileptics (as a whole) had lower serum manganese than controls.

Primary epileptics prior to therapy had lower manganese level than primary epileptics under therapy or secondary epileptics under therapy but still statistically non significant.

There were no significant correlation between duration of epilepsy and serum and urinary level of manganese among primary epileptics prior to start therapy. However it was found that duration of epilepsy lower serum manganese level and this was statistically significant.

Serum zinc levels was lower in primary epileptics, while were still lower than that of the controls when each antiepileptic drug was considered separately. We found that primary epileptics receiving CBZ had no significant difference before and after therapy, while there was significant difference between them and controls. Patients receiving VPA had significant difference before and after therapy.

Regarding urinary zinc level, it was significantly lower among all primary epileptics than controls. When each AED was considered separately, we found that primary epileptics receiving CBZ and VPA had no significant difference before and after therapy.

Both serum and urinary levels of zinc in secondary epileptics showed no significant difference between cases and controls.

As regards serum and urinary levels of both aluminium and cobalt, there were no statistically significant difference between epilptics (primary prior to therapy, primary under therapy and secondary under therapy) and controls. Age, sex, duration of therapy and duration of epilepsy had no effect.

Anticonvulsant drugs does not affect serum or urinary levels of both aluminium or cobalt. Type, etiology or frequency of seizures had no effect on levels of aluminium and cobalt.

We can come to the conclusion that trace elements, namely copper, manganese and zinc are significantly altered with epilepsy with further alteration after AED, however, being a cause or a result waits for further elucidation.

Key words: Epilepsy – Convulsions – Trace elements – Copper – Zinc – Manganese – Cobalt - Aluminium - Antiepileptic drugs.

CONTENTS

INTRODUCTION	1
AIM OF THE WORK	2
REVIEW OF THE LITERATURE	
Epilepsy	3
Aluminium	38
Manganese	43
Cobalt	50
Zinc	53
Copper	84
SUBJECT AND METHODS	104
RESULTS	110
DISCUSSION	137
SUMMARY AND CONCLUSION	155
RECOMENDATION	159
REFFERENCES	160
ARABIC SUMMARY	206

LISTS OF TABLES

- **Table (1):** New antiepileptic drugs available in 1993 (p.31)
- **Table (2):** Zinc content of different body organs (p.55)
- **Table (3):** Recommended Zn intakes (mg/day) (p.59)
- **Table (4):** Zn metalloenzymes and binding proteins (p.62)
- **Table (5):** Clinical manifestations of severe human zn deficiency (p.67)
- **Table (6):** The copper proteins known to be present in human beings (p.92)
- **Table (7):** Copper metalloenzymes and binding proteins (p.93)
- **Table (8):** Copper binding proteins (p.93)
- **Table (9):** Atomic absorption instruction (p.106)
- **Table (10):** Raw data of the primary epileptics prior to therapy (p. 110)
- **Table (11):** Raw data of the primary epileptics under therapy (p. 111)
- **Table (12):** Raw data of the secondary epileptics under therapy (p. 112)
- Table (13): Raw data of the control (p.113)

- Table (14): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics prior to start of therapy (groupI) versus controls (group VI) (P.114)
- Table (15): Mean values of serum and urinary Manganese,
 Aluminium, Cobalt, Zinc and Copper among
 primary epileptics under therapy (group II)
 versus controls (group VI) (P.115)
- Table (16): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among secondary epileptics under therapy (group III) versus controls (group VI) (P.116)
- Table (17): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics prior to start of therapy (group I) versus those under therapy (group II) (P.117)
- Table (18): Mean values of serum and urinary Manganese,
 Aluminium, Cobalt, Zinc and Copper among
 primary epileptics prior to start of therapy
 (groupI) versus secondary epileptics under
 therapy (group III) (P.118)
- Table (19): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics under therapy (group II) versus secondary epileptics under therapy (group III) (P.119)

- Table (20): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics receiving (VPA) versus control (group VI) (p.120)
- Table (21): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics receiving (CBZ) versus control (group VI) (p.121)
- Table (22): Mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among epileptics receiving (CBZ) versus patients receiving (VPA) (P.122)
- Table (23): Correlation matrix between duration of epilepsy with mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics under therapy (group II) (P.123)
- **Table** (24): Correlation matrix between duration of epilepsy with mean values of serum and urinary Manganese, Aluminium, Cobalt, Zinc and Copper among primary epileptics prior to start of therapy (group I) (P.124).